{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.1","upperLimit":"56.8","value":"48.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with CR + PR, as assessed by the IRC using the Lugano criteria, for participants receiving the optimal dose of duvelisib for at least one cycle of study therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib PO BID at a starting dose of 75 mg for the first 2 cycles, followed by a mandatory reduction to 25 mg BID thereafter for those participants with CR, PR or SD, in 28-day cycles (dose determined in Optimization Phase).","id":"OG000","title":"Expansion Phase"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-treat (mITT): all participants who received at least one dose of study drug. Here, 'Overall Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure. As pre-specified, efficacy analysis using IRC assessment reported for the Expansion Phase only.","reportingStatus":"POSTED","timeFrame":"56 days (2 cycles; 28-day cycles)","title":"ORR as Assessed by the Independent Review Committee (IRC) Using the Lugano Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}